LL-37 // Antimicrobial Peptide
The body's primary antimicrobial defense peptide — a 37-amino acid fragment of cathelicidin that directly destroys bacteria, viruses, and fungi while modulating immune response. LL-37 penetrates and disrupts biofilms, making it invaluable for chronic infections that resist conventional antibiotics. Used extensively in Lyme disease, mold/CIRS, and chronic infection protocols.
Direct kill. Biofilm breach. Immune activation.
LL-37 works through three simultaneous mechanisms that make it fundamentally different from conventional antibiotics. First, it directly disrupts microbial cell membranes through electrostatic interaction — bacteria can't easily develop resistance to this mechanism. Second, it penetrates biofilms, the protective matrix that shields chronic infections. Third, it modulates the innate immune system, enhancing the body's own defense capabilities.
Low and slow — this isn't a blunt instrument.
LL-37 dosing is conservative by design. The peptide is potent enough that high doses can trigger excessive immune activation (Herxheimer-type reactions). Start low, assess response, and titrate up only if needed. Many practitioners use a pulsed protocol — several days on, several days off — to match the body's natural immune cycling.
From innate immunity to clinical infection protocols.
LL-37 (cathelicidin) is the only human cathelicidin — a class of antimicrobial peptides that serve as the body's first-line defense against infection. It's produced by neutrophils, macrophages, and epithelial cells, and is found in wound fluid, breast milk, sweat, and mucosal surfaces.
Research demonstrates broad-spectrum antimicrobial activity against bacteria (including MRSA, E. coli, Pseudomonas), fungi (Candida), and enveloped viruses. Critically, LL-37 disrupts biofilms — the protective matrix that makes chronic infections like Lyme disease, chronic sinusitis, and device-associated infections resistant to conventional antibiotics.
In the biohacking community, LL-37 has become a cornerstone of Lyme disease protocols and CIRS (Chronic Inflammatory Response Syndrome) recovery, where biofilm-protected organisms drive chronic symptoms. It's typically used alongside other immune-modulating peptides like Thymosin Alpha-1 and VIP.
LL-37 vs. other immune/antimicrobial peptides.
| Compound | Mechanism | Target | Biofilm? | Best For |
|---|---|---|---|---|
| LL-37 | Membrane disruption | Broad-spectrum | Yes — primary strength | Chronic infections, Lyme, CIRS |
| Thymosin Alpha-1 | T-cell activation | Adaptive immunity | No | Immune reconstitution |
| KPV | NF-κB inhibition | Gut inflammation | No | IBD, gut inflammation |
| BPC-157 | Growth factors | Tissue repair | No | Healing, GI support |
| VIP | Immune regulation | CIRS/Th balance | No | Mold illness, CIRS |
What to watch for.
LL-37's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.
- Herxheimer reaction (flu-like symptoms from pathogen die-off)
- Injection site redness and swelling (common, transient)
- Fatigue and malaise (immune activation response)
- Headache (especially early in protocol)
- Joint pain flare (can indicate immune response to biofilm organisms)
- Mild fever (sign of immune engagement — not necessarily negative)
- GI upset (rare at standard doses)
- Dose-dependent — start low to minimize reaction severity
- CBC with differential (immune cell counts)
- CRP / ESR (inflammation markers — track changes)
- C3a / C4a (complement activation — CIRS marker)
- TGF-beta 1 (inflammatory cytokine)
- CD57 (Lyme-specific immune marker)
- MSH (melanocyte-stimulating hormone — CIRS)
- MMP-9 (matrix metalloproteinase — inflammation)
- Vitamin D (25-OH) — modulates LL-37 expression
- Thymosin Alpha-1 for comprehensive immune reconstitution
- VIP for CIRS protocol (after LL-37 addresses infection load)
- BPC-157 for gut support if GI symptoms arise
- NAC (N-Acetyl Cysteine) for biofilm disruption support
- Vitamin D3 at 5,000–10,000 IU/day — upregulates endogenous LL-37
- Activated charcoal or binders during die-off phase
- Lyophilized: refrigerate at 2–8°C (36–46°F)
- Reconstituted: refrigerate, use within 14–21 days
- Protect from light and heat — peptide is relatively fragile
- Do not freeze reconstituted solution
- Shorter stability than BPC-157 — reconstitute smaller volumes
- Research grade: confirm ≥98% HPLC purity on COA
Compounds that complement LL-37.
The biofilm breaker — your frontline against chronic infection.
LL-37 fills a gap that no antibiotic can: direct biofilm penetration combined with broad-spectrum antimicrobial activity and immune modulation. For Lyme disease, chronic sinusitis, CIRS, and any condition where biofilm-protected organisms drive symptoms, it's arguably the most important peptide in the protocol. The key is managing the die-off: start at 50mcg, expect Herxheimer reactions, and use binders and BPC-157 for support. Vitamin D supplementation at 5,000–10,000 IU/day is non-negotiable — it upregulates your body's own LL-37 production. Get CD57, C4a, and TGF-beta 1 tested before and after to objectively track immune response.
Our free Protocol Guide includes the complete Shield Stack with LL-37 — chronic infection protocols, CIRS recovery sequencing, blood work panels, and immune support stacking.